Psyence Biomedical (PBM) Cash from Operations (2023)

Psyence Biomedical (PBM) recorded quarterly Cash from Operations of 1592080.0 in Q1 2023.

Psyence Biomedical (PBM) Cash from Operations (2023) Analysis & Trends

Psyence Biomedical's Cash from Operations history runs 1 years deep, the most recent figure standing at 1592080.0 for Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -1.67 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -12.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -2.49 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.43 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn 1.08 Bn

Historic Data

Download Data
DateValue
Mar 31, 2023 -1.59 Mn
Mar 31, 2023 -1.59 Mn